Compare KEP & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEP | ILMN |
|---|---|---|
| Founded | 1961 | 1998 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 18.9B |
| IPO Year | N/A | 2000 |
| Metric | KEP | ILMN |
|---|---|---|
| Price | $17.26 | $132.07 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $114.93 |
| AVG Volume (30 Days) | 427.1K | ★ 1.6M |
| Earning Date | 11-14-2025 | 10-30-2025 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | ★ 122.08 | N/A |
| EPS | ★ 9.13 | 4.46 |
| Revenue | ★ $69,245,145,923.00 | $4,288,000,000.00 |
| Revenue This Year | $5.38 | N/A |
| Revenue Next Year | $2.36 | $2.08 |
| P/E Ratio | ★ $3.79 | $29.62 |
| Revenue Growth | ★ 5.27 | N/A |
| 52 Week Low | $6.68 | $68.70 |
| 52 Week High | $18.29 | $153.06 |
| Indicator | KEP | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 68.77 |
| Support Level | $17.13 | $126.44 |
| Resistance Level | $17.83 | $129.72 |
| Average True Range (ATR) | 0.37 | 4.12 |
| MACD | -0.11 | -0.41 |
| Stochastic Oscillator | 50.83 | 79.08 |
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment. Geographically, it derives maximum revenue from Domestic operations.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.